expression by targeting mRNAs in a sequence-specific manner (29) . There is significant overlap in the effects of miRs: one miR can negatively regulate many genes, and conversely, one gene can be negatively regulated by many miRs.
Production of mature miRs requires Dicer, an endoribonuclease III type enzyme that cleaves pre-microRNAs into mature miRs (10, 13) . Several miRs are thought to modulate hepatocyte proliferation, either positively or negatively. miR-21 enhances cyclin D1 expression, likely based on effects on RhoB (22) . miR-221 increases hepatocyte proliferation via effects on Arnt (14) . Conversely, miRs 21, 26a, 34a, and 150 inhibit hepatocyte proliferation (3, 22, 31, 34) .
These findings point toward a role for Dicer in liver regeneration. Studying Dicer function in adults is complicated by neonatal lethality in Dicer-null mice (1) . To determine the role of miRNAs during liver regeneration, we generated adult Dicer-null mice by infecting floxed Dicer mice with our previously reported adeno-associated virus 8 (AAV8) vector expressing Cre from the major urinary protein (MUP) promoter (11) to achieve hepatocyte-specific miRNA elimination.
In this study, we identify Dicer as an essential mediator of hepatocyte proliferation after partial hepatectomy via production of miR-221 that releases a check on hepatocyte proliferation by inhibiting p27.
MATERIALS AND METHODS

Animals.
Mice in which the Dicer1 gene was flanked by loxP sites [Dicer (fl/fl) ] were obtained from the Jackson Laboratory (Bar Harbor, ME) and housed under standard conditions. To decrease variability and take advantage of the expression properties of the AAV8 virus, all mice used in this study were males injected with virus between 6 and 8 wk old. Genotyping was performed as previously described (11) .
Adeno-associated virus-8 vector. Hepatocyte-specific MUP-Creadeno-associated virus-8 (AAV8) (Cre ϩ ) and MUP-eGFP-AAV8 (Cre Ϫ ) viruses were produced as described previously (11) . Cre ϩ or Cre Ϫ virus was injected into Dicer (fl/fl) mice to produce hepatocytespecific Dicer-null mice [Dicer (fl/fl) ; Cre ϩ ] or control mice [Dicer (fl/fl) ; Cre Ϫ ]. Tail vein injection were performed as described previously (12) . Experiments were performed 2 wk after tail vein injection of 3.0 ϫ 10 10 DNase-resistant particles/mouse to allow time for the recombination event to occur.
Two-thirds hepatectomy. All surgeries were performed according to the National Institutes of Health (NIH) guidelines for the humane treatment of laboratory animals, according to the "Guide for the Care and Use of Laboratory Animals" (NIH publication No. 86-23) and with the approval of the Institutional Animal Care and Use Committee of Vanderbilt University Medical School. Mice were anesthetized with 60 mg/kg ketamine (Hospira, Lake Forest, IL) and 7 mg/kg xylazine (Phoenix Pharmaceuticals, Burlingame, CA) and were posi-tioned supine. A transverse abdominal incision was made and the xiphoid process was excised. The median and left lateral lobes of the liver were eviscerated, ligated, and processed. At tissue recovery, mice were anesthetized and weighed, and the remaining liver was excised for analysis. Tissue for sections was snap frozen in liquid nitrogen, fixed in 10% neutral buffered formalin, or preserved in RNAlater (Life Technologies, Carlsbad, CA).
Proliferation assay. Mice received 1 mg of intraperitoneal injection of 5-bromo-2-deoxyuridine (BrdU; BD Pharmingen, Brea, CA) 2 h before euthanasia. Staining for BrdU was performed on fixed paraffinembedded liver sections, according to the manufacturer's instructions (ImmPRESS reagent kit, Vector Laboratories, Burlingame, CA). Proliferation index was quantified as the percentage of labeled hepatocyte nuclei that stained with BrdU. Primary antibody was rat anti-BrdU (Santa Cruz Biotechnology, Dallas, TX). At least three high-power fields (ϫ400) were counted to quantify the percentage of labeled hepatocytes to determine the proliferation index.
Quantitative polymerase chain reaction. Total RNA was purified from cell culture or 25 mg of liver tissue preserved in RNAlater using a miRNeasy mini kit (Qiagen, Valencia, CA) and reverse transcribed into complementary DNA (cDNA) using a high-capacity cDNA reverse transcription kit (Applied Biosystems, San Luis Obispo, CA). The cDNA template was amplified using inventoried TaqMan gene expression assays (Applied Biosystems) under standard conditions. Ten nanograms of RNA were used for miRNA-specific cDNA synthesis with the TaqMan MicroRNA reverse transcription kit (Applied Biosystems) and TaqMan microRNA assays (Applied Biosystems). A StepOnePlus (Applied Biosystems) was used for all real-time PCR. All mRNA levels were normalized to GAPDH. All miRNA levels were normalized to snoRNA202. Relative changes in mRNA expression and miRNA expression were determined using the comparative CT method. TaqMan probe and primer sets (Applied Biosystems) used were Dicer1 (Mm01337223_m1), Ccna2 (Mm00438063_m1), Ccnd1 (Mm03053889_s1), Cdk1 (Mm00772472_m1), Cdkn1a (Mm01303209_m1), Gadd45b (Mm00435121_g1), SOCS2 (Mm00850544_g1), Cdkn1b (Mm00438168_m1), Cdkn1c (Mm00438170_m1), Jun (Mm00495062_s1), Arnt (Mm01255878_ m1), p53 (Mm01731287_m1), GAPDH (Mm99999915_g1), snoRNA202 (001232), and mmu-miR-221-3p (000524).
Protein sample preparation and Western blot analysis. Whole cell liver lysates were prepared by homogenizing 50 mg of frozen tissue in lysis buffer (50 mM HEPES, 10% glycerol, 1 mM EDTA, 50 mM NaF, 1 mM dithiothreitol, and 0.1% NP40) containing phosphatase and protease inhibitors (Sigma-Aldrich, St. Louis, MO). Samples were sonicated for 10 s and clarified by centrifugation. Protein concentration was determined by Bradford assay (Bio-Rad, Hercules, CA). Protein was denatured and separated by SDS-PAGE in 4 -12% NuPAGE Bis-Tris precast gels (Life Technologies) and transferred to a polyvinylidene difluoride membrane (EMD Millipore, Billerica, MA). All antibody dilutions were done in 5% nonfat dry milk in TBS. Primary antibodies used were mouse anti-␤-actin (Abcam, Cambridge, MA), rabbit anti-Smad1/5/8 (Santa Cruz Biotechnology), rabbit anti-p-Smad1/5/8 (Cell Signaling Technology, Danvers, MA), rabbit anti-cyclin A (Santa Cruz Biotechnology), rabbit anti-SOCS2 (Santa Cruz Biotechnology), rabbit anti-Cyclin D1 (Abcam), rabbit monoclonal anti-p-STAT 3 (Abcam), rabbit anti-p-p38 (Cell Signaling Technology), rabbit anti-cdk1 (Millipore), rabbit anti-x-Jun (Abcam), rabbit anti-p-ERK1/2 (Cell Signaling Technology), rabbit antiAkt (Cell Signaling Technology), rabbit anti-p-Akt (Cell Signaling Technology), rabbit anti-SOCS3 (Cell Signaling Technology), rabbit anti-p21 (Abcam), rabbit anti-PCNA (Cell Signaling Technology), rabbit anti-p27 (Cell Signaling Technology), and rabbit anti-p57 (Pierce, Waltham, MA). Secondary antibodies were anti-horseradish peroxidase-conjugated species-specific secondary antibodies (Promega, Madison, WI). Western blot analyses for each individual protein were run simultaneously on two separate gels to accommodate the large number of samples and time points. In all cases, controls were run in adjacent lanes on the same gel. After transfer, the two membranes containing all of the time points were processed and exposed simultaneously. ␤-Actin as a loading control was similarly analyzed using the same lysate. Two gels were run and processed simultaneously. All white space in the image represents discontinuous images. ␤-Actin loading controls are included below groups of proteins that were analyzed from the same sample. Western blot films were scanned and analyzed quantitatively by ImageJ software (NIH, Bethesda, MD). In all cases, at least three mice in each group were analyzed.
Primary hepatocyte culture and transfection. Primary hepatocytes were isolated using collagenase perfusion, as described previously (5). Cell suspensions were plated onto a 24-well plate (50,000 cells/well) or a 96-well plate (10,000 cells/well) and maintained in MEM with 7% FBS. Cells were transfected with 20 nM of miR-221 mirVana mimic (Ambion) using the reverse transfection protocol of the Lipofectamine RNAiMax reagent (Life Technologies), according to the manufacturer's protocol. CyQUANT Direct Cell Proliferation Assay (Invitrogen) was used to measure proliferation, according to the manufacturer's instructions. Primary hepatocytes were harvested 2 wk after tail vein injection of AAV8.
In vivo miR delivery. Each animal received Invivofectamine 3.0 reagent (Invitrogen) and a dose of 10 g/mouse of control (empty) or 10 g/mouse miR-221 mirVana mimic (Ambion) 48 h before 2/3 hepatectomy and immediately after 2/3 hepatectomy, according to the manufacturer's protocol (23) .
Data analysis. Comparisons were performed using a two-tailed unpaired Student's t-test for pairwise comparisons and two-way ANOVA for multiple comparisons as appropriate. All statistical tests used at least three different samples for each time point. Statistical significance is defined by P Ͻ 0.05. All error bars in the figures express means Ϯ SE.
RESULTS
Dicer is constitutively expressed in the quiescent liver and decreased after 2/3 hepatectomy. We first examined the effect of 2/3 hepatectomy on Dicer transcription using quantitative PCR (qPCR). Dicer expression decreased tõ 50% of basal levels 6 h after 2/3 hepatectomy and 40% of basal levels 24 h after 2/3 hepatectomy, and then returned toward prehepatectomy levels by 5 days (Fig. 1 ). In contrast, Dicer mRNA levels did not change after sham operation (data not shown). Dicer is necessary for normal liver regeneration. To determine the role of Dicer in liver regeneration, Cre ϩ or Cre Ϫ AAV8 was injected into 6-wk-old Dicer (fl/fl) mice. Recombination was confirmed using PCR (Fig. 1B) . Two-thirds hepatectomy was performed 2 wk later. Liver mass was not restored 7 days after 2/3 hepatectomy in Dicer (fl/fl) ; Cre ϩ mice compared with controls (Dicer (fl/fl) ;Cre Ϫ ) ( Fig. 2A) . To investigate the mechanism of this finding, hepatocyte proliferation was assessed at various time points after 2/3 hepatectomy. Dicer (fl/fl) ; Cre ϩ mice demonstrated reduced hepatocyte proliferation 36 and 48 h after 2/3 hepatectomy compared with controls by BrdU staining (Fig. 2, B and C) . These results suggest that Dicer in hepatocytes is critical for normal hepatocyte proliferation after partial hepatectomy.
Loss of Dicer affects cell cycle genes. We next performed qPCR and Western blot analysis to determine the expression of cell cycle genes that play important roles in hepatocyte proliferation. When compared with control, hepatocyte-specific loss of Dicer led to decreased cyclin A2 mRNA expression 24 and 48 h after 2/3 hepatectomy (Fig. 3A) , and decreased protein levels of cyclin A2 24 h after 2/3 hepatectomy (Fig. 3, B and G). Cyclin D1 and CDK1 expression was unchanged (data not shown).
To determine the mechanism of decreased cyclin A2 expression, we analyzed mRNA expression for genes known to regulate cyclin A, including p27, p53, p21, and p57 (18) . Dicer (fl/fl) ;Cre ϩ mice exhibited increased p27 mRNA and protein expression 36 h after 2/3 hepatectomy, and decreased p57 protein at baseline and 36 h after 2/3 hepatectomy compared with control (Fig. 3, C, D, E, G) . p21 and p53 mRNA expression was unchanged after 2/3 hepatectomy (data not shown). To determine which miRNAs might be responsible for the observed mRNA changes, we noted that p27 and p57 are known targets of miR-221 (3, 33) . Therefore, we investigated the expression of miR-221 in Dicer (fl/fl) ;Cre ϩ mice. miR-221 was decreased to half of normal values in the liver of these mice both at baseline and after 2/3 hepatectomy compared with control (Fig. 3F) . These results suggest that Dicer regulates miRs and target genes known to be critical for cell cycle progression.
Dicer knockout affects signaling pathways known to be important for liver regeneration. We next investigated IL-6/ JAK2/STAT3 signaling, important pathways in liver regeneration. In Dicer (fl/fl) ;Cre ϩ mice, IL-6 is higher compared with the control group at baseline, and JAK2 is lower at 6 h after 2/3 qPCR demonstrates hepatocyte-specific Dicer KO decreased cyclin-A2 mRNA expression compared with controls 24 and 48 h after 2/3 hepatectomy (*P Ͻ 0.05). B: qPCR demonstrates hepatocyte-specific Dicer KO increased cyclin A compared with controls (*P Ͻ 0.05). C: qPCR demonstrates hepatocyte-specific Dicer KO increases p27 mRNA 36 h after 2/3 hepatectomy. D: qPCR demonstrates increased protein levels at 36 h (*P Ͻ 0.05). E: hepatocyte-specific loss of Dicer leads to an increase in protein level of p57 at baseline and 24 h after 2/3 hepatectomy (*P Ͻ 0.05; **P Ͻ 0.01). F: miR-221 is reduced to 50% of normal levels in hepatocyte-specific Dicer null mice (***P Ͻ 0.001, **P Ͻ 0.01). G: Western blots used for the analysis with ImageJ software. Time after hepatectomy and genotype (top) and protein (left) are described. All white space in the image represents discontinuous gel bands. ␤-Actin-loading controls are included below groups of proteins that were analyzed from the same sample. A: qPCR demonstrates hepatocyte-specific Dicer KO increases IL-6 protein levels compared with those in controls at baseline (*P Ͻ 0.05). B: qPCR demonstrates hepatocyte-specific Dicer KO decreases JAK2 protein level compared with than in controls 6 h after 2/3 hepatectomy (*P Ͻ 0.05). C: qPCR demonstrates Dicer KO increases p-STAT3 compared with that in controls 6 h after 2/3 hepatectomy (**P Ͻ 0.01). D: qPCR demonstrates hepatocyte-specific Dicer KO decreases jun mRNA expression compared with that in controls 6 h after 2/3 hepatectomy. E: qPCR demonstrates hepatocyte-specific Dicer KO increases jun protein at baseline and decreases it 24 h after 2/3 hepatectomy (*P Ͻ 0.05). F and G: hepatocyte-specific Dicer KO decreases SOCS2 mRNA by qPCR level 24 h after 2/3 hepatectomy (*P Ͻ 0.05) and increases protein at baseline and at 24 h after 2/3 hepatectomy (*P Ͻ 0.05) compared with those levels in controls. H: qPCR demonstrates hepatocyte-specific Dicer KO decreases the p-Akt-to-Akt ratio compared with that in controls 6 h after 2/3 hepatectomy. I: Western blots were used for the analysis with ImageJ software. All white space in the image represents discontinuous gel bands. ␤-Actin loading controls are included below groups of proteins that were analyzed from the same sample.
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hepatectomy compared with controls (Fig. 4, A, B, and I) . pSTAT3 in Dicer-null mice is higher than that of control mice (Fig. 4, C and I) . Since both IL-6 and pSTAT3 are thought to increase hepatocyte proliferation after hepatectomy, these results suggest loss of Dicer should increase hepatocyte proliferation. Therefore, we conclude that effects on IL-6 and pSTAT3 do not explain changes due to Dicer on liver regeneration. We next evaluated the MAPK signaling pathway. In Dicer (fl/fl) ; Cre ϩ mice, Jun mRNA is lower 6 h after 2/3 hepatectomy, and protein levels are lower 24 h after 2/3 hepatectomy, compared with controls (Fig. 4, D, E, and I) . At baseline, Jun protein is higher at baseline in Dicer (fl/fl) ;Cre ϩ mice compared with controls. p-p38 was not different between Dicer (fl/fl) ;Cre ϩ mice and controls after 2/3 hepatectomy (data not shown). Because there is no difference in p-ERK1/2 (data not shown), the results suggest that Dicer does not affect classical MAPK signaling during liver regeneration.
We next examined the effect of loss of Dicer on SOCS2 and SOCS3, proteins that suppress liver regeneration. In Dicer (fl/fl) ; Cre ϩ mice, SOCS2 mRNA, and protein were lower 24 h after 2/3 hepatectomy compared with controls, suggesting that Dicer upregulates SOCS2 after 2/3 hepatectomy (Fig. 4, F, G, and I) . SOCS3 was not changed after 2/3 hepatectomy in Dicer (fl/fl) ; Cre ϩ mice compared with control. Hepatocyte-specific loss of Dicer suppressed the rise of p-Akt compared with Akt 6 h after 2/3 hepatectomy (Fig. 4, H and I ) but did not affect GADD45b or relative or absolute levels of p-Smad (data not shown).
Effects of loss of Dicer on cell cycle proteins in hepatocytes are rescued by miR-221.
To determine the effect of loss of Dicer on hepatocytes themselves, we performed in vitro experiments using primary hepatocyte cultures. First, we confirmed that miR-221 was reduced in Dicer-null hepatocytes. qPCR demonstrated minimal production of miR-221 in these cells compared with controls (Fig. 5A) .
To determine whether the proliferative defect in Dicer-null hepatocytes is the result of an effect on miR-221, we added a miR-221 mimic to the cell culture. We found the normally low but present initial proliferation of primary hepatocytes was lower in Dicer-null hepatocytes compared with wild-type hepatocytes 48 h after plating (Fig. 5B) .
To further determine the mechanism of this effect, we determined how miR-221 influenced the aryl hydrocarbon receptor nuclear translocator (Arnt), p27, and p57, all known targets of miR-221 that affect the cell cycle (9, 32, 33) . Dicer-null primary hepatocytes exhibited increased expression of Arnt, p27, and p57 48 h after plating compared with controls. The addition of the miR-221 mimic decreased Arnt, p27, and p57 expression. These findings suggest miR-221 regulates these genes (Fig. 5, C-E) .
miR-221 restores hepatocyte proliferation in hepatocytespecific Dicer-null mice after 2/3 hepatectomy. To determine whether the primary function of Dicer in controlling hepatocyte proliferation in vivo after 2/3 hepatectomy was via miR-221, we injected Dicer (fl/fl) ; Cre ϩ mice with miR-221 to see whether hepatocyte proliferation was restored. First, we confirmed that injecting 20 nM miR-221 mimic (Applied Biosystems) led to increased levels of miR-221 in the liver of these mice (Fig. 6A) . The higher level of miR-221 at 36 h is likely due to the second dose of the mimic administered after 2/3 hepatectomy. We then examined whether miR-221 could restore hepatocyte proliferation in Dicer (fl/fl) ; Cre ϩ mice. Injection of miR-221 in hepatocyte-specific Dicer-null mice restored hepatocyte proliferation compared with vehicle 36 h after 2/3 hepatectomy (Fig. 6, B and C) . These results suggest that the Dicer's mechanism of action is via inhibition of miR-221 to regulate hepatocyte proliferation after 2/3 hepatectomy.
To further investigate this, we examined the effect of miR-221 on levels of p27. When compared with control mice, Dicer (fl/fl) ;Cre ϩ mice had higher levels of p27. The addition of the miR-221 mimic decreased p27 to below control levels (Fig.  6D) , suggesting that p27 is a target of miR-221. MiR-221 inhibits liver regeneration in wild-type mice. To determine whether the liver regeneration phenotype of hepatocyte-specific Dicer-null mice could be attributed to effects on miR-221, we injected wild-type mice with cholesterol tagged to-221 or scrambled control. Mice receiving the to-221 exhibited decreased hepatocyte proliferation compared with scrambled control (Fig. 7) . This phenocopies our findings in the Dicer-null mice. Taken together with our previous results, A: qPCR revealed that injection of miR221 increased miR-221 expression in the hepatocyte-specific Dicer KO liver (***P Ͻ 0.001; **P Ͻ 0.01). B: miR-221 mimic increased hepatocyte proliferation to normal levels 36 h after 2/3 hepatectomy (**P Ͻ 0.01; *P Ͻ 0.05). C: immunohistochemistry for BrdU injected 2 h before euthanasia revealed that miR-221 mimic increased hepatocyte proliferation in hepatocyte-specific Dicer KO mice (scale bar ϭ 100 m). D: miR-221 mimic decreases p27 mRNA 36 h after 2/3 hepatectomy (*P Ͻ 0.05).
these findings suggest the principal effect of Dicer on hepatocyte proliferation is via miR-221.
DISCUSSION
Liver regeneration depends on a multitude of transcriptional changes with large numbers of mRNAs differentially expressed during the process. How this process is regulated at the global level poses many unanswered questions. As miRs potentially regulate many RNAs at once, we sought to determine the role of Dicer during liver regeneration. Our studies suggest Dicer plays an important role in determining the rate of hepatocyte proliferation and restoration of liver mass after partial hepatectomy. Our findings that Dicer is required for production of miR-221, which, in turn, is required to suppress p27, provide a direct mechanism for the effect of Dicer. Importantly, specific inhibition of miR-221 phenocopies effects of Dicer deletion, providing direct confirmation of a mechanism by which Dicer produces a miR that inhibits an inhibitor of hepatocyte proliferation to allow normal liver regeneration. The functional significance of this is that Dicer functions to allow rapid liver regeneration after injury to reestablish homeostasis.
These studies provide a direct link between Dicer and physiological liver regeneration. Although other miRs have been implicated in hepatocyte proliferation and liver regeneration, previous reports demonstrated increased proliferation in cell lines or in oncologic models (9, 18, 32) . This report is the first to use specific deletion of portions of the miR pathway to demonstrate a role in the physiological process of liver regeneration.
Our data suggest a mechanism by which Dicer affects levels of cyclin A, a protein known to be required for progression through S phase. In particular, Dicer production of miR-221 suppresses p27, which is known to inhibit cyclin A and inhibit cell proliferation (2, 14, 15, 16, 30) .
Our findings suggest that regulation of gene expression by Dicer is complex and multifaceted. In particular, in addition to increasing p27, loss of Dicer leads to an increase in p57 protein. p57 is a cyclin-dependent kinase inhibitor, and elevations in this protein may also slow hepatocyte proliferation. mRNA for p57 was not decreased in Dicer-null mice after partial hepatectomy, although p57 protein was, suggesting Dicer regulates its expression via posttranscriptional mechanisms. Decrease in p-AKT in Dicer-null mice suggests another possible mechanism, as p-AKT is critical for regeneration after partial hepatectomy (15) .
Dicer also influences other genes important for hepatocyte proliferation. IL-6 expression is thought to play a role in enhancing regeneration (25) , so the higher IL-6 levels in hepatocyte-specific Dicer-null mice at baseline are unlikely to explain inhibition of regeneration. A similar argument applies for JAK/STAT signaling, which has been implicated as essential for liver regeneration (4) . Our data show whereas JAK2 is decreased in Dicer-null mice, pSTAT3 is increased. The decreased proliferation in the Dicer-null mice, therefore, is likely not due to effects on the JAK/STAT pathway. SOCS2 is a growth hormone antagonist that supports ubiquitination and degradation of the growth hormone receptor (GHR), and loss of SOCS2 enhances liver regeneration (19) . Elevated levels of SOCS2 at baseline in the Dicer-null mice could, therefore, lead to decreased levels of GHR and contribute to the decreased hepatocyte proliferation observed in these mice.
Our study has a number of limitations. It is possible that in the 2 wk between virus injection and the recombination, liver injury occurs and cholesterol metabolism is affected consistent with other reports (20) . It is also possible that our observed effects are due to a defect in zonation or circadian rhythms associated with loss of Dicer (6, 26) . We did not find differences in cholesterol levels or bilirubin in Dicer-null mice, and histology was normal in these mice (data not shown), which provides some evidence that liver injury from removal of Dicer is not responsible for the defect in liver regeneration. Furthermore, our studies with primary hepatocytes supporting the in vivo findings make defects in circadian rhythms less likely to be responsible for the observations. Finally, these results were performed in male mice only because of the limitations of the AAV8 promoter (11) . It is possible that our results are not generalizable to females.
A major experimental hurdle with important clinical relevance is the inability to either drive or suppress hepatocyte proliferation in various clinical settings, including drug overdose and small-for-size syndrome after liver resection or transplantation. This is due to the relatively nonspecific nature of the proliferation pathways and off-target effects of proposed pharmaceuticals. By the delineation of miR-based pathways to drive or suppress hepatocyte proliferation, it may be possible to develop nontoxic strategies. For example, on the basis of these studies, miR-221 agonists or antagonists might be useful to modulate hepatocyte proliferation as a clinical therapy.
